Diabetes drug semaglutide put to the test in chilean patients

NCT ID NCT05533632

Completed Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the safety and tolerability of a once-weekly injection of semaglutide (0.5 or 1.0 mg) in 104 Chilean adults with type 2 diabetes over 24 weeks. Participants received the drug in escalating doses, with regular blood and urine tests to monitor side effects. The main goal was to count any adverse events, while also tracking changes in blood sugar control (HbA1c).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a once-weekly injection for diabetes)
What this could lead to: If successful, this study could confirm that semaglutide is safe and well-tolerated for managing type 2 diabetes in Chilean patients.
What could go wrong: This is a small, completed Phase 4 safety study, not designed to prove major new benefits. Results may not apply to other populations or show unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2

Contacts and locations

Locations

Hospital Padre Hurtado

Santiago, Región Metropolitana, 8880465, Chile
Hospital San Juan de Dios_Santiago, Región Metropolitana

Santiago, Región Metropolitana, 8350429, Chile
Servicios Médicos Godoy Limitada

Santiago, Región Metropolitana, 7500710, Chile

More trials for these conditions

Other studies related to the condition(s) this trial covers.